ATE503830T1 - Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon - Google Patents

Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon

Info

Publication number
ATE503830T1
ATE503830T1 AT05791326T AT05791326T ATE503830T1 AT E503830 T1 ATE503830 T1 AT E503830T1 AT 05791326 T AT05791326 T AT 05791326T AT 05791326 T AT05791326 T AT 05791326T AT E503830 T1 ATE503830 T1 AT E503830T1
Authority
AT
Austria
Prior art keywords
variants
viral
present
virus
hepatitis
Prior art date
Application number
AT05791326T
Other languages
English (en)
Inventor
Julie Sheldon
Berta Rodes
Vincent Soriano
Angeline Bartholomeusz
Original Assignee
Melbourne Health
Fundacion Investigacion Y Educacion En Sida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905615A external-priority patent/AU2004905615A0/en
Application filed by Melbourne Health, Fundacion Investigacion Y Educacion En Sida filed Critical Melbourne Health
Application granted granted Critical
Publication of ATE503830T1 publication Critical patent/ATE503830T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
AT05791326T 2004-09-28 2005-09-28 Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon ATE503830T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905615A AU2004905615A0 (en) 2004-09-28 Viral variants and applications thereof
PCT/AU2005/001489 WO2006034545A1 (en) 2004-09-28 2005-09-28 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof

Publications (1)

Publication Number Publication Date
ATE503830T1 true ATE503830T1 (de) 2011-04-15

Family

ID=36118509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05791326T ATE503830T1 (de) 2004-09-28 2005-09-28 Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon

Country Status (6)

Country Link
US (1) US7927601B2 (de)
EP (1) EP1799814B1 (de)
AT (1) ATE503830T1 (de)
DE (1) DE602005027226D1 (de)
WO (1) WO2006034545A1 (de)
ZA (1) ZA200702632B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP1499712A4 (de) 2002-04-12 2008-04-16 Melbourne Health Hepatitis-b-virusvarianten mit verminderter empfindlichkeit gegenüber nukleosidanalogen und verwendung davon
JP2008534020A (ja) 2005-04-08 2008-08-28 メルボルン ヘルス 抗ウイルス性のヌクレオシド剤に耐性を示すｂ型肝炎ウイルスのバリアントおよびその応用法
AU2006230802A1 (en) 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
CA2626672A1 (en) * 2005-10-21 2007-04-26 Melbourne Health Antiviral resistance mutants and applications thereof
KR101489342B1 (ko) 2006-06-06 2015-02-11 멜버른 헬스 항바이러스 내성 돌연변이의 검출 및 용도
WO2011039612A1 (en) * 2009-10-01 2011-04-07 Ranjit Chauhan Detection and use of antiviral resistance mutations
RU2667524C2 (ru) 2011-04-21 2018-09-21 Ионис Фармасьютикалз, Инк. Модулирование экспрессии вируса гепатита b (hbv)
CN102807971B (zh) * 2011-06-09 2014-02-12 复旦大学附属华山医院 高表达耐拉米夫定hbv病毒肝癌细胞株
US10376576B2 (en) 2014-06-02 2019-08-13 Isa Pharmaceuticals B.V. Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis B virus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309379A1 (en) 2000-06-09 2001-12-09 Thomas Bock Viral variants and uses therefor
JP4502642B2 (ja) * 2002-02-07 2010-07-14 メルボルン ヘルス ヌクレオシドアナログに対する感受性の変化を有するウイルス変種およびその使用
EP1499712A4 (de) * 2002-04-12 2008-04-16 Melbourne Health Hepatitis-b-virusvarianten mit verminderter empfindlichkeit gegenüber nukleosidanalogen und verwendung davon
EP1546190A2 (de) 2002-10-01 2005-06-29 Gilead Sciences, Inc. Hbv veränderungen verbunden mit verringerter anfälligkeit gegenüber adefovir
AU2004285983B2 (en) 2003-10-21 2012-06-28 Alfred Health HBV variants detection and application

Also Published As

Publication number Publication date
ZA200702632B (en) 2008-08-27
US7927601B2 (en) 2011-04-19
WO2006034545A1 (en) 2006-04-06
US20100047281A1 (en) 2010-02-25
DE602005027226D1 (de) 2011-05-12
EP1799814B1 (de) 2011-03-30
EP1799814A4 (de) 2008-02-20
EP1799814A1 (de) 2007-06-27

Similar Documents

Publication Publication Date Title
ATE503830T1 (de) Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon
SG161255A1 (en) Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
Hatzakis et al. HBV virological assessment
Ning et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)
Lutchman et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy
EP1476543A4 (de) Virusvarianten mit veränderter empfindlichkeit gegenüber nukleosidanalogen und verwendungen davon
Xu et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus
Cubero et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
Brichler et al. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia
Attar et al. A new twist to a chronic HCV infection: occult hepatitis C
Tillmann et al. GB virus-C infection in patients infected with the human immunodeficiency virus
Mixson-Hayden et al. Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users
EP2404933A3 (de) HBV-Variantenerkennung und Anwendung
Saito et al. Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis?
ATE534729T1 (de) Hepatitis-b-virus-dna-polymerase und oberflächenantigen-varianten und methoden iher verwendung
Gerken et al. Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA
Ursu et al. Laboratory diagnosis for optimize therapy of B hepatitis virus infection by using biochemical and molecular biology methods
Hong et al. Role of HBsAg testing in the management of patients with chronic HBV
Gupta et al. Analysis of mutations within the 5′ untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India
Krekulova et al. Genotypic distribution of hepatitis B virus in the Czech Republic: a possible association with modes of transmission and clinical outcome
Berzsenyi et al. GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease
Santer et al. A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression
Cannon et al. Evidence for action of ribavirin through the hepatitis C virus RNA polymerase
ATE321892T1 (de) Hiv-nachweisverfahren und reagenzien dafür
Schulte‐Frohlinde et al. Significance of antibodies to the recombinant E2 protein of hepatitis G virus in haemodialysis patients

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties